| Product Code: ETC13189635 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Pleural Diseases Market was valued at USD 0.82 Billion in 2024 and is expected to reach USD 1.2 Billion by 2031, growing at a compound annual growth rate of 5.00% during the forecast period (2025-2031).
The Global Pleural Diseases Market is driven by factors such as the increasing prevalence of respiratory diseases, including pleural effusion and pleural infections, an aging population, and advancements in diagnostic technologies. Pleural diseases are characterized by the accumulation of fluid or inflammation in the pleural space surrounding the lungs, leading to symptoms such as chest pain and difficulty breathing. Treatment options for pleural diseases include thoracentesis, pleurodesis, and surgery, with a growing emphasis on minimally invasive procedures. Key players in the market include medical device companies, pharmaceutical companies, and healthcare providers offering pleural disease management solutions. With a focus on early diagnosis and personalized treatment approaches, the Global Pleural Diseases Market is expected to continue growing as healthcare systems strive to improve patient outcomes and quality of life.
The Global Pleural Diseases Market is experiencing significant growth due to the increasing prevalence of respiratory conditions and the rising adoption of minimally invasive procedures. Key trends in the market include the development of advanced diagnostic tools for early detection, the introduction of innovative treatment options such as pleuroscopy and thoracoscopy, and the integration of technology like robotics and artificial intelligence in pleural procedures. Additionally, there is a growing focus on personalized medicine and targeted therapies for better patient outcomes. Opportunities in the market lie in the expansion of healthcare infrastructure in developing countries, the rising healthcare expenditure globally, and the increasing awareness about the importance of early diagnosis and treatment of pleural diseases. Overall, the market is poised for further growth and innovation in the coming years.
The Global Pleural Diseases Market faces several challenges, including limited awareness about pleural diseases among healthcare professionals and patients, leading to underdiagnosis and delayed treatment. Additionally, the lack of standardized diagnostic procedures and treatment guidelines for various pleural conditions complicates patient management and contributes to inconsistencies in care delivery. The high cost of diagnostic tests and treatment options, coupled with limited reimbursement options in some regions, can also hinder access to quality care for patients with pleural diseases. Furthermore, the complex nature of pleural conditions, such as pleural effusion or mesothelioma, presents clinical challenges in terms of accurate diagnosis, disease staging, and treatment selection, highlighting the need for ongoing research and development efforts in this field.
The global pleural diseases market is driven by several key factors, including the increasing prevalence of respiratory disorders such as pneumonia, tuberculosis, and lung cancer, which often lead to pleural diseases. Additionally, the rising geriatric population worldwide, who are more susceptible to developing pleural diseases, is fueling market growth. Technological advancements in diagnostic tools and treatment options for pleural diseases are also driving market expansion, enabling early detection and more effective management of these conditions. Moreover, the growing awareness about the importance of early diagnosis and treatment of pleural diseases among healthcare professionals and patients is contributing to market demand. Overall, the increasing burden of respiratory illnesses and the focus on improving patient outcomes are significant drivers propelling the global pleural diseases market forward.
Government policies related to the Global Pleural Diseases Market primarily focus on improving access to healthcare services, promoting research and development of innovative treatments, and enhancing patient outcomes. Regulatory bodies such as the FDA in the United States and the EMA in Europe play a crucial role in ensuring the safety and efficacy of pleural disease therapies. Governments also support initiatives to increase awareness about pleural diseases, facilitate early diagnosis, and provide financial assistance for patients in need. Furthermore, policymakers aim to streamline approval processes for new treatments and foster collaborations between industry stakeholders and healthcare providers to address the challenges faced by patients with pleural diseases. Overall, government policies in this sector aim to drive advancements in treatment options, improve patient care, and ultimately reduce the burden of pleural diseases on healthcare systems worldwide.
The Global Pleural Diseases Market is projected to experience steady growth in the coming years due to an increasing prevalence of respiratory conditions, such as pneumonia, tuberculosis, and lung cancer, which often lead to pleural diseases. Advancements in diagnostic technologies, such as thoracoscopy and imaging modalities, coupled with the development of novel treatment options including pleurodesis and tunneled pleural catheters, are expected to drive market expansion. Additionally, rising healthcare expenditure, growing awareness about early disease diagnosis, and a rising geriatric population prone to pleural diseases are likely to contribute to market growth. However, challenges such as limited access to healthcare in developing regions and the high cost of treatment may impede market progression to some extent. Overall, the Global Pleural Diseases Market is anticipated to witness positive growth trends in the foreseeable future.
In the global Pleural Diseases market, Asia is expected to witness significant growth due to high prevalence of respiratory diseases and increasing healthcare expenditure in countries like China and India. North America is projected to dominate the market owing to advanced healthcare infrastructure and rising adoption of innovative treatment options. Europe is also a key market with increasing awareness about pleural diseases and favorable reimbursement policies. The Middle East and Africa region is likely to experience steady growth due to improving healthcare facilities and rising investments in healthcare. Latin America is anticipated to show moderate growth due to growing prevalence of respiratory disorders and increasing focus on improving healthcare access in countries like Brazil and Mexico.
Global Pleural Diseases Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Pleural Diseases Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Pleural Diseases Market Revenues & Volume, 2021 & 2031F |
3.3 Global Pleural Diseases Market - Industry Life Cycle |
3.4 Global Pleural Diseases Market - Porter's Five Forces |
3.5 Global Pleural Diseases Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Pleural Diseases Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.7 Global Pleural Diseases Market Revenues & Volume Share, By Diagnostic Tools, 2021 & 2031F |
3.8 Global Pleural Diseases Market Revenues & Volume Share, By Treatment Modalities, 2021 & 2031F |
3.9 Global Pleural Diseases Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Global Pleural Diseases Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Pleural Diseases Market Trends |
6 Global Pleural Diseases Market, 2021 - 2031 |
6.1 Global Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Pleural Diseases Market, Revenues & Volume, By Pleurisy, 2021 - 2031 |
6.1.3 Global Pleural Diseases Market, Revenues & Volume, By Pleural Effusion, 2021 - 2031 |
6.1.4 Global Pleural Diseases Market, Revenues & Volume, By Pneumothelioma, 2021 - 2031 |
6.1.5 Global Pleural Diseases Market, Revenues & Volume, By Mesothelioma, 2021 - 2031 |
6.1.6 Global Pleural Diseases Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Pleural Diseases Market, Revenues & Volume, By Imaging Techniques, 2021 - 2031 |
6.2.3 Global Pleural Diseases Market, Revenues & Volume, By Molecular Diagnostics, 2021 - 2031 |
6.2.4 Global Pleural Diseases Market, Revenues & Volume, By Thoracoscopy, 2021 - 2031 |
6.2.5 Global Pleural Diseases Market, Revenues & Volume, By Pleuroscopy, 2021 - 2031 |
6.3 Global Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Pleural Diseases Market, Revenues & Volume, By Medications, 2021 - 2031 |
6.3.3 Global Pleural Diseases Market, Revenues & Volume, By Thoracentesis and Pleurodesis, 2021 - 2031 |
6.3.4 Global Pleural Diseases Market, Revenues & Volume, By Minimally Invasive Interventions, 2021 - 2031 |
6.3.5 Global Pleural Diseases Market, Revenues & Volume, By Surgical Interventions, 2021 - 2031 |
6.4 Global Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Pleural Diseases Market, Revenues & Volume, By Hospitals and Clinics, 2021 - 2031 |
6.4.3 Global Pleural Diseases Market, Revenues & Volume, By Diagnostic Centers, 2021 - 2031 |
6.4.4 Global Pleural Diseases Market, Revenues & Volume, By Research and Academic Institution, 2021 - 2031 |
7 North America Pleural Diseases Market, Overview & Analysis |
7.1 North America Pleural Diseases Market Revenues & Volume, 2021 - 2031 |
7.2 North America Pleural Diseases Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.4 North America Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
7.5 North America Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
7.6 North America Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Latin America (LATAM) Pleural Diseases Market, Overview & Analysis |
8.1 Latin America (LATAM) Pleural Diseases Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Pleural Diseases Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
8.4 Latin America (LATAM) Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
8.5 Latin America (LATAM) Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
8.6 Latin America (LATAM) Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
9 Asia Pleural Diseases Market, Overview & Analysis |
9.1 Asia Pleural Diseases Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Pleural Diseases Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
9.4 Asia Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
9.5 Asia Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
9.6 Asia Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
10 Africa Pleural Diseases Market, Overview & Analysis |
10.1 Africa Pleural Diseases Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Pleural Diseases Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
10.4 Africa Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
10.5 Africa Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
10.6 Africa Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
11 Europe Pleural Diseases Market, Overview & Analysis |
11.1 Europe Pleural Diseases Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Pleural Diseases Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
11.4 Europe Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
11.5 Europe Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
11.6 Europe Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
12 Middle East Pleural Diseases Market, Overview & Analysis |
12.1 Middle East Pleural Diseases Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Pleural Diseases Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Pleural Diseases Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Pleural Diseases Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
12.4 Middle East Pleural Diseases Market, Revenues & Volume, By Diagnostic Tools, 2021 - 2031 |
12.5 Middle East Pleural Diseases Market, Revenues & Volume, By Treatment Modalities, 2021 - 2031 |
12.6 Middle East Pleural Diseases Market, Revenues & Volume, By End User, 2021 - 2031 |
13 Global Pleural Diseases Market Key Performance Indicators |
14 Global Pleural Diseases Market - Export/Import By Countries Assessment |
15 Global Pleural Diseases Market - Opportunity Assessment |
15.1 Global Pleural Diseases Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Pleural Diseases Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
15.3 Global Pleural Diseases Market Opportunity Assessment, By Diagnostic Tools, 2021 & 2031F |
15.4 Global Pleural Diseases Market Opportunity Assessment, By Treatment Modalities, 2021 & 2031F |
15.5 Global Pleural Diseases Market Opportunity Assessment, By End User, 2021 & 2031F |
16 Global Pleural Diseases Market - Competitive Landscape |
16.1 Global Pleural Diseases Market Revenue Share, By Companies, 2024 |
16.2 Global Pleural Diseases Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |